pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs

Biochemical Pharmacology

Volumn 57, Issue 9, 1999, Pages 1047-1058

  Raghunand, Natarajan ^a   Martínez Zaguilán, Raul ^a   Wright, Stephen H ^a   Gillies, Robert J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Compartmentation; Exocytosis; Mathematical model; Multidrug resistance; Organic cation transport; Vacuolar type H+ ATPase

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTIPORTER; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; MITOXANTRONE;

ACTIVE TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CATION EXCHANGE; CELL PH; CELL VACUOLE; CONTROLLED STUDY; DRUG TRANSPORT; ENDOSOME; EXOCYTOSIS; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MODEL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ACETIC ACID; ANIMALS; ANTINEOPLASTIC AGENTS; CELL MEMBRANE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENDOSOMES; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; ION TRANSPORT; MEMBRANE POTENTIALS; MICE; MICE, SCID; MODELS, BIOLOGICAL; ORGANELLES; P-GLYCOPROTEIN; PROTON-TRANSLOCATING ATPASES; TUMOR CELLS, CULTURED; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 0345389967     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00021-0     Document Type: Article

References (69)

1. Nielsen D., Skovsgaard T. P-glycoprotein as multidrug transporter A critical review of current multidrug resistant cell lines . Biochim Biophys Acta. 1139:1992;169-183.
2. Dalton W.S. Is p-glycoprotein a potential target for reversing clinical drug resistance? Curr Opin Oncol. 6:1994;595-600.
3. Clynes M. Cellular models for multiple drug resistance in cancer. In Vitro Cell Dev Biol. 29A:1993;171-179.
4. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 62:1993;385-427.
5. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M.V., Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1658.
6. Pastan I., Gottesman M.M., Ueda K., Lovelace E., Rutherford A.V., Willingham M.C. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA. 85:1988;4486-4498.
7. Ueda K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA. 84:1987;3004-3008.
8. Grant C.E., Valdimarsson G., Hipfner D.R., Almquist K.C., Cole S.P.C., Deeley R.G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54:1994;357-361.
9. +-ATPase subunit C is overexpressed in multidrug-resistant HL60 cells. Biochem Biophys Res Commun. 182:1992;675-681.
10. +-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol. 57:1999;1037-1046.
11. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 53:1993;1475-1479.
12. Izquierdo M.A., Scheffer G.L., Flens M.J., Schroeijers A.B., van der Valk P., Scheper R.J. Major vault protein LRP-related multidrug resistance. Eur J Cancer. 32A:1996;979-984.
13. Schuurhuis G.J., Broxterman H.J., de Lange J.H.M., Pinedo H.M., van Heijningen T.M.H., Kuiper C.M., Scheffer G.L., Scheper R.J., van Kalken C.K., Baak J.P.A., Lankelma J. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer. 64:1991;857-861.
14. De Isabella P., Capranico G., Zunino F. The role of topoisomerase II in drug resistance. Life Sci. 48:1991;2195-2205.
15. Klohs W.D., Steinkampf R.W., Leopold W.R., Fry D.W. Potentiation of adriamycin, trimetrexate and an AMSA analog (CI-921) cytotoxicities by amiodarone and reserpine in multidrug resistant P388 cells. Proc Am Assoc Cancer Res. 28:1987;298-302.
16. Klohs W.D., Steinkampf R.W., Havlick M.J., Jackson R.J. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells Reversal by calcium channel blockers and calmodulin antagonists . Cancer Res. 46:1986;4352-4356.
17. Klohs W.D., Steinkampf R.W., Besserer J.A., Fry D.W. Cross resistance of pleiotropically drug resistant P388 leukemia cells to the lipophilic antifolates trimetrexate and BW 301U. Cancer Lett. 31:1986;253-260.
18. Spoelstra E.C., Dekker H., Schuurhuis G.J., Broxterman H.J., Lankelma J. P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Biochem Pharmacol. 41:1991;349-359.
19. Ruetz S., Gros P. A mechanism For P-glycoprotein action in multidrug resistance Are we there yet? Trends Pharmacol Sci. 15:1994;260-263.
20. Molinari A., Cianfriglia M., Meschini S., Calcabrini A., Arancia G. P-glycoprotein expression in the Golgi apparatus of multidrug-resistant cells. Int J Cancer. 59:1994;789-795.
21. Taylor C.W., Dalton W.S., Parrish P.R., Gleason M.C., Bellamy W.T., Thompson F.H., Roe D.J., Trent J.M. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer. 63:1991;923-929.
22. Dalton W.S., Cress A.E., Alberts D.S., Trent J.M. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res. 48:1988;1882-1888.
23. Harker W.G., Slade D.L., Dalton W.S., Meltzer P.S., Trent J.M. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 49:1989;4542-4549.
24. Mulder H.S., Lankelma J., Dekker H., Broxterman H.J., Pinedo H.M. Daunorubicin efflux against a concentration gradient in non-P-glycoprotein multidrug-resistant lung-cancer cells. Int J Cancer. 59:1994;275-281.
25. 4 and structurally related conjugates. J Biol Chem. 269:1994;27807-27810.
26. Sehested M., Skovsgaard T., van Deurs B., Winther-Neilsen H. Increase in nonspecific adsorptive endocytosis in anthracycline- and vinca alkaloid-resistant Ehrlich ascites tumor cell lines. J Natl Cancer Inst. 78:1987;171-179.
27. Sehested M., Skovsgaard T., van Deurs B., Winther-Neilson H. Increased plasma membrane traffic in daunorubicin resistant P388 leukemic cells Effect of daunorubicin and verapamil . Br J Cancer. 56:1987;747-751.
28. Sognier M.A., Zhang Y., Eberle R.L., Sweet K.M., Altenberg G.A., Belli J.A. Sequestration of doxorubicin in vesicles in a multidrug-resistant cell line (LZ-100). Biochem Pharmacol. 48:1994;391-401.
29. Seidel A., Hasmann M., Loser R., Bunge A., Schaefer B., Herzig I., Steidtmann K., Dietel M. Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and drug-resistant gastric carcinoma EPG85-257 cells. Virchows Arch. 426:1995;249-256.
30. Dubowchik G.M., Padilla L., Edinger K., Firestone R.A. Reversal of doxorubicin resistance and catalytic neutralization of lysosomes by a lipophilic imidazole. Biochim Biophys Acta. 1191:1994;103-108.
31. Sehested M., Skovsgaard T., Roed H. The carboxylic ionophore monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells. Biochem Pharmacol. 37:1988;3305-3310.
32. Schindler M., Grabski S., Hoff E., Simon S.M. Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycin-resistant cells (MCF-7adr). Biochemistry. 35:1996;2811-2817.
33. Gervasoni J.E. Jr, Fields S.Z., Krishna S., Baker M.A., Rosado M., Thuraisamy K., Hindenburg A.A., Taub R.N. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res. 51:1991;4955-4963.
34. Klohs W.D., Steinkampf R.W. The effect of lysosomatropic agents and secretory inhibitors on anthracycline retention and activity in multiple drug-resistant cells. Mol Pharmacol. 34:1988;180-185.
35. Simon S.M., Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA. 91:1994;3497-3504.
36. +-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol. 265:1993;C1015-C1029.
37. 31P magnetic resonance spectroscopy. Biochem Pharmacol. 57:1999;309-312.
38. 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am J Physiol. 267:1994;C195-C203.
39. 31P magnetic resonance spectroscopy in murine tumors. Br J Cancer. 72:1995;905-911.
40. Goldman D.E. Potential, impedance, and rectification in membranes. J Gen Physiol. 27:1943;37-60.
41. Spoelstra E.C., Westerhoff H.V., Dekker H., Lankelma J. Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells. Eur J Biochem. 207:1992;567-579.
42. Toffoli G., Simone F., Gigante M., Boiocchi M. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines. Biochem Pharmacol. 48:1994;1871-1881.
43. Slapak C.A., Mizunuma N., Kufe D.W. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood. 84:1994;3113-3121.
44. Schlemmer S.R., Sirotnak F.M. Functional studies of P-glycoprotein in inside-out plasma membrane vesicles derived from murine erythroleukemia cells overexpressing MDR3. J Biol Chem. 269:1994;31059-31066.
45. Pritchard J.B., Sykes D.B., Walden R., Miller D.S. ATP-dependent transport of tetraethylammonium by endosomes isolated from rat renal cortex. Am J Physiol. 266:1994;F966-F976.
46. Van Dyke R.W., Faber E.D., Meijer D.K.F. Sequestration of organic cations by acidified hepatic endocytic vesicles and implications for biliary excretion. J Pharmacol Exp Ther. 261:1992;1-11.
47. Forgac M. Structure, function and regulation of the coated vesicle V-ATPase. J Exp Biol. 172:1992;155-169.
48. + exchanger of rabbit renal brush-border membrane vesicles. J Biol Chem. 263:1988;19494-19497.
49. + exchanger of renal brush-border membrane vesicles. Am J Physiol. 258:1990;F597-F605.
50. Moseley R.H., Jarose S.M., Permoad P. Organic cation transport by rat liver plasma membrane vesicles Studies With tetraethylammonium . Am J Physiol. 263:1992;G775-G785.
51. + exchanger of rabbit renal brush border membranes. Pflugers Arch. 429:1995;313-324.
52. Moseley R.H., Van Dyke R.W. Organic cation transport by rat liver lysosomes. Am J Physiol. 268:1995;G480-G486.
53. Murphy R.F., Powers S., Cantor C.R. Endosome pH measured in single cells by dual fluorescence flow cytometry Rapid acidification of insulin to pH 6 . J Cell Biol. 98:1984;1757-1762.
54. Fuchs R., Male P., Mellman I. Acidification and ion permeabilities of highly purified rat liver endosomes. J Biol Chem. 264:1989;2212-2220.
55. Skovsgaard T., Nissen N.I. Membrane transport of anthracyclines. Pharmacol Ther. 18:1982;293-311.
56. Dalmark M. Characteristics of doxorubicin transport in human red blood cells. Scand J Clin Lab Invest. 41:1981;633-639.
57. Dalmark M., Hoffman E.K. Doxorubicin (Adriamycin) transport in Ehrlich ascites tumour cells Comparison with transport in human red blood cells. Scand J Clin Lab Invest. 43:1983;241-248.
58. Dordal M.S., Winter J.N., Atkinson A.J. Jr. Kinetic analysis of P-glycoprotein-mediated doxorubicin efflux. J Pharmacol Exp Ther. 263:1992;762-766.
59. 31P NMR of small biological samples . NMR Biomed. 8:1995;72-78.
60. Tanner J.E. Intracellular diffusion of water. Arch Biochem Biophys. 224:1993;416-428.
61. i homeostasis in multidrug-resistant (MDR) cells Further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein . Biochemistry. 32:1993;11042-11056.
62. Awasthi S., Sharma R., Awasthi Y.C., Belli J.A., Frenkel E.P. The relationship of doxorubicin binding to membrane lipids with drug resistance. Cancer Lett. 63:1992;109-116.
63. Guiral M., Viratelle O., Westerhoff H.V., Lankelma J. Cooperative P-glycoprotein mediated daunorubicin transport into DNA-loaded plasma membrane vesicles. FEBS Lett. 346:1994;141-145.
64. Wadkins R.M., Roepe P.D. Biophysical aspects of P-glycoprotein-mediated multidrug resistance. Int Rev Cytol. 171:1997;121-165.
65. 31P NMR study . Magn Reson Med. 32:1994;303-309.
66. Stubbs M., Rodrigues L., Howe F.A., Wang J., Jeong K.S., Veech R.L., Griffiths J.R. Metabolic consequences of a reversed pH gradient in rat tumors. Cancer Res. 54:1994;4011-4016.
67. Vayuvegula B., Slater L., Meador J., Gupta S. Correction of altered plasma membrane potentials A possible mechanism of cyclosporin A and verapamil reversal of pleiotropic drug resistance in neoplasia . Cancer Chemother Pharmacol. 22:1988;163-168.
68. Hasmann M., Valet G.K., Tapiero H., Treverrow K., Lampidis T. Membrane potential differences between Adriamycin-sensitive and -resistant cells as measured by flow cytometry. Biochem Pharmacol. 38:1989;305-312.
69. Demant E.J.F., Sehested M., Jensen P.B. A model for computer simulation of P-glycoprotein and transmembrane ΔpH-mediated anthracycline transport in multidrug-resistant tumor cells. Biochim Biophys Acta. 1055:1990;117-125.